Skip to main content
Premium Trial:

Request an Annual Quote

Hundreds to Go

Pharmaceutical company Sanofi-Aventis is eliminating “hundreds of jobs,” reports Ed Silverman at Pharmalot. The cuts come in the wake of Sanofi’s acquisition of Genzyme, he say, adding that some R&D operations will be shuffled between its New Jersey and Massachusetts sites, and that there will be layoffs in sales, particularly in the cardiovascular and oncology groups.

“The cutbacks are hardly surprising, though,” Silverman notes. “A few weeks ago, Sanofi disclosed plans to cut another $2.9 billion in costs in hopes of coping with upcoming expiration of patents on big-selling meds, notably the Plavix bloodthinner and Avapro high blood pressure medicine. R&D costs, for instance, are in the process of being cut by 12 percent from 2008 to about $1.1 billion, excluding Genzyme.”

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.